<DOC>
	<DOCNO>NCT02491528</DOCNO>
	<brief_summary>This multicenter , randomize , open , parallel group , active-controlled study . The study period 25 26 week , include screening period 1-2 week treatment period 24 week .</brief_summary>
	<brief_title>A Phase III Study Insulin Aspart Injection Evaluate Efficacy Safety</brief_title>
	<detailed_description>After screen visit , patient meet inclusion criterion meet exclusion criterion randomize experimental group control group . The subject experimental arm receive insulin aspart injection combine basal insulin ( Lantus ® ) , subject control arm receive NovoRapid ® ( active control ) combine basal insulin ( Lantus ® ) . The experimental drug control drug administer subcutaneously prior three meal ( administer immediately meal necessary ) , basal insulin ( Lantus ® ) administer bedtime . The treatment period 24 week , subject follow clincic cetres 1 , 2 , 4 , 8 , 12 , 18 , 24 week treatment . At end 24-week treatment , adverse event continue , subject follow recovery stabilization AEs .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Patients diagnose diabetes； BMI≤35.0 kg/m2； Insulin therapy least 3 month recruitment； HbA1c7~13 % Patients study drug allergy； Liver kidney impairment； Liver kidney impairment； use systemic steroid treatment past 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>